GoldenGolden
Amphivena Therapeutics

Amphivena Therapeutics

Amphivena Therapeutics is a bi-functional antibody therapy.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

September 2019
Amphivena Therapeutics raises a $62,000,000 series C round from Aju IB Investment, Clough Capital Partners, Franklin M. Berger, Industrial Investors, Kaitai Capital, Korys, MPM Capital, Merieux Developpement, NanoDimension, Nawton Limited, Qi Ming Venture Partners, QiMing Venture Partners and Tekla Capital Management.
July 15, 2013
Amphivena Therapeutics raises a $14,000,000 series A round.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Amphivena Therapeutics
December 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer...
Amphivena Therapeutics
December 6, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in...
Amphivena Therapeutics
November 9, 2020
www.prnewswire.com:443
/PRNewswire/ -- Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in...
BioSpace
May 29, 2020
BioSpace
Initial data from the Phase 1 dose escalation trial in 18 patients with advanced solid tumors shows AMV564 administered subcutaneously was well tolerated, with no dose-limiting toxicities
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.